ストックスクリーナーアプリを入手
9.58
0.42%
0.04
プレマーケット:
9.76
0.18
+1.88%
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 - Sahm
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences - Sahm
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Sahm
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating at buy - Investing.com
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Sahm
US$600M Telix Pharmaceuticals (TLX) convertible bond settlement noted - Stock Titan
Telix Pharmaceuticals (TLX) files 6-K on AGM and proxy materials - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Sahm
Telix (NASDAQ: TLX) refinances with US$600M 2031 convertible bonds - Stock Titan
Telix Pharmaceuticals stock gains on FDA acceptance of NDA - Investing.com
Telix Pharmaceuticals stock gains on FDA acceptance of NDA By Investing.com - Investing.com South Africa
Revenue growth on track for undervalued ASX healthcare stock - Morningstar Australia
Telix Strengthens Board with Additional Director Appointments - Sahm
Telix Pharmaceuticals (NASDAQ: TLX) expands board with two new NEDs - Stock Titan
Telix Appoints David Gill as Non-Executive Director - Sahm
[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3.63M indirect shares - Stock Titan
Telix (TLX) COO reports ordinary shares, ADRs and option-like awards - Stock Titan
Telix Pharmaceuticals (TLX) files 20-F/A to correct exhibit links - Stock Titan
Telix Pharmaceuticals (TLX) director reports 595,000 shares held via Forellan - Stock Titan
Telix (TLX) CEO details ADRs, options and large indirect stake - Stock Titan
Telix Pharmaceuticals (TLX) director discloses 3,719 Ordinary Shares - Stock Titan
Telix Pharmaceuticals Limited (TLX) Stock Price, News, Quote & History - Yahoo Finance
Telix (NASDAQ: TLX) resubmits FDA NDA for Pixclara brain cancer imaging agent - Stock Titan
Latest TLX NewsTelix to Showcase Urology Pipeline at Upcomi... - Stock Titan
Stock of the day: Telix Pharmaceuticals - ig.com
Telix Signals Upcoming Escrow Share Release - Colitco
How new prostate scans could change care: Telix hosts doctor Q&A - Stock Titan
Global prostate scan registry taps AI to predict survival - Stock Titan
Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz
Telix leaders to speak at Oppenheimer and TD Cowen, sessions streamed live - Stock Titan
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):